GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akero Therapeutics Inc (NAS:AKRO) » Definitions » EPS without NRI

Akero Therapeutics (Akero Therapeutics) EPS without NRI : $-2.88 (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Akero Therapeutics EPS without NRI?

Akero Therapeutics's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-1.02. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.88.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Akero Therapeutics's EPS without NRI or its related term are showing as below:

AKRO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -4.7   Med: 0.3   Max: 9.1
Current: -4.7

AKRO's 3-Year EPS without NRI Growth Rate is ranked worse than
62.19% of 1304 companies
in the Biotechnology industry
Industry Median: 5.5 vs AKRO: -4.70

Akero Therapeutics's EPS (Diluted) for the three months ended in Dec. 2023 was $-1.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.88.

Akero Therapeutics's EPS (Basic) for the three months ended in Dec. 2023 was $-1.02. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.88.


Akero Therapeutics EPS without NRI Historical Data

The historical data trend for Akero Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akero Therapeutics EPS without NRI Chart

Akero Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial -2.90 -2.52 -2.89 -2.87 -2.89

Akero Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.49 -0.55 -0.60 -0.71 -1.02

Competitive Comparison of Akero Therapeutics's EPS without NRI

For the Biotechnology subindustry, Akero Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akero Therapeutics's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akero Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Akero Therapeutics's PE Ratio without NRI falls into.



Akero Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akero Therapeutics  (NAS:AKRO) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Akero Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Akero Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Akero Therapeutics (Akero Therapeutics) Business Description

Traded in Other Exchanges
Address
601 Gateway Boulevard, Suite 350, South San Francisco, CA, USA, 94080
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
Executives
Jonathan Young officer: Chief Operating Officer C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FL, SOUTH SAN FRANCISCO CA 94080
Andrew Cheng director, officer: President & CEO 170 HARBOR WAY, 3RD FLOOR, C/O AKERO THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Catriona Yale officer: Chief Development Officer C/O AKERO THERAPEUTICS INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
William Richard White officer: Chief Financial Officer C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Timothy Rolph officer: Chief Scientific Officer C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY, 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
G. Walmsley Graham director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Tomas J. Heyman director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Jane Henderson director C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Patrick Lamy officer: See Remarks AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Skorpios Trust other: Former 10% owner 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Montrago Trustees Ltd other: Former 10% owner 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Blue Horizon Enterprise Ltd other: Former 10% owner 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Ezbon International Ltd other: Former 10% owner 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Seth Loring Harrison director 230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Chou Judy director C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BLVD, SUITE 350, SOUTH SAN FRANCISCO CA 64080